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ABSTRACT 
The discovery in the early 2000’s that magnetic nanoparticles (MNPs) complexed to nonviral or viral 
vectors can, in the presence of an external magnetic field, greatly enhance gene transfer into cells has 
raised much interest. This technique, called magnetofection, was initially developed mainly to 
improve gene transfer in cell cultures, a simpler and more easily controllable scenario than in vivo 
models. These studies provided evidence for some unique capabilities of magnetofection. 
Progressively, the interest in magnetofection expanded to its application in animal models and led to 
the association of this technique with another technology, magnetic drug targeting (MDT). This 
combination offers the possibility to develop more efficient and less invasive gene therapy strategies 
for a number of major pathologies like cancer, neurodegeneration and myocardial infarction. The goal 
of MDT is to concentrate MNPs functionalized with therapeutic drugs, in target areas of the body by 
means of properly focused external magnetic fields. The availability of stable, nontoxic MNP-gene 
vector complexes now offers the opportunity to develop magnetic gene targeting (MGT), a variant of 
MDT in which the gene coding for a therapeutic molecule, rather than the molecule itself, is delivered 
to a therapeutic target area in the body. This article will first outline the principle of magnetofection, 
subsequently describing the properties of the magnetic fields and MNPs used in this technique. Next, 
it will review the results achieved by magnetofection in cell cultures. Last, the potential of MGT for 
implementing minimally invasive gene therapy will be discussed. 
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INTRODUCTION 
Gene therapy has undergone a remarkable development in the last 20 years. Particularly important 
advances have been made in the improvement of gene transfer and expression technology, with 
current efforts focusing on the design of safer and longer-expression gene vectors as well as systems 
possessing cell-type specificity for transgene delivery and regulatability of its expression by small 
molecules.  
The association of viral vector-based gene delivery with nanotechnology now offers the possibility to 
develop more efficient and less invasive gene therapy strategies for a number of major pathologies 
including, but not limited to, cancer, neurodegeneration and myocardial infarction. This approach 
combines Magnetic Drug Targeting (MDT) and magnetofection, two methodologies based on the use 
of magnetic nanoparticles (MNPs). The concept of MDT was introduced by Widder et al. [1] and its 
goal was to concentrate magnetically responsive therapeutic complexes in target areas of the body by 
means of external magnetic fields. So far, the main application of MDT has been cancer therapy. 
Typically, magnetic microparticles (µm sized) or MNPs (nm sized) associated to a therapeutic drug 
are intravascularly injected near the tumor blood supply and are concentrated into the tumor by means 
of an external magnetic field. This strategy has shown promising results in clinical trials [2, 3, also see 
below]. Magnetofection is a methodology developed in the early 2000’s [4, also see below]. It is 
based on the association of MNPs with nonviral or viral vectors in order to optimize gene delivery in 
the presence of a magnetic field. The availability of stable, nontoxic MNP-gene vector complexes now 
offers the opportunity to implement magnetic gene targeting (MGT) in suitable animal models. MGT 
represents a variant of MDT in which the gene coding for a therapeutic molecule, rather than the 
molecule itself, is delivered to a therapeutic target area in the body. The advantage of MGT over MDT 
lies in the fact that in the former, when a vector complex unit transduces a target cell it generates large 
numbers of therapeutic molecules (amplification effect) for an extended period of time. If these are 
secreted molecules they will be released into the intercellular space.   
This article will first outline the principle of magnetofection, subsequently describing the properties of 
the magnetic fields and MNPs used in this technique. Next, it will review the results achieved by 
magnetofection in cell cultures. Last, the potential of MGT for implementing minimally invasive gene 
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therapy will be discussed. For a highly comprehensive review on magnetically-enhanced nucleic acid 
delivery the reader is referred to a recent article by Plank e. al  (5).  
 
MAGNETOFECTION 
As indicated above, magnetofection is a methodology based on the association of MNPs with gene 
vectors in order to enhance gene transfer in the presence of a magnetic field. It was developed by 
Christian Plank and collaborators for gene transfer in cell cultures and in vivo using MNP-naked DNA 
complexes or MNP-viral vector complexes [4]. In this context the principle of magnetofection in cells 
was assumed to be simple (Fig. 1): the MNP-DNA complex is added to a culture of adherent cells and 
a magnet, placed close below the bottom of the flask or plate, attracts the magnetic complexes to the 
bottom where they come in close contact with the cells and are physically internalized, without any 
particular effect of the magnetic force on the endocytic uptake mechanism [6]. For MNP-viral vector 
complexes it was thought that the magnetic field brought the complexes close to the cells thus favoring 
their internalization through viral receptor-mediated mechanisms. This results in a transduction 
improvement that in some cases is remarkable. For instance, in HEK293 cell cultures exposed to 
MNP-adenoviral vector complexes, magnetofection may induce over a 50-fold increase in 
transduction levels  (Fig. 2). For MNP-adenoviral vector complexes, the internalization mechanism 
outlined above does not hold, as suggested by the fact that certain cell lines (e.g., NIH3T3, K562 and 
primary human peripheral blood lymphocytes) which express little or no coxsackie virus and 
adenovirus (CAR) receptors and are therefore refractory to adenovectors, can be successfully 
transduced by magnetofection using MNP-adenovector complexes [4]. Furthermore, ultrastructural 
analysis of MNP-recombinant adenovirus (RAd) complexes by electron and atomic force microscopy 
showed structurally intact adenoviruses fully surrounded by magnetic particles that occasionally 
bridged several virus particles [7]. Since this configuration would prevent virions from binding to their 
cell receptors, a still unknown internalization mechanism is likely to be involved. Also, kinetic studies 
with gold/iron oxide-based MNP-RAd complexes in adenovirus resistant cell lines provided additional 
evidence for a non receptor-mediated internalization mechanism for RAd-MNP complexes [8]. 
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Regardless of the mechanisms by which magnetofection enhances gene transfer, over the years this 
technique has demonstrated to be highly effective in cell cultures (see below) and constitutes a 
promising tool for the implementation of MGT in vivo (see below). The commercial availability of 
magnetofection reagents has made this methodolgy readily accessible to nonspecialist researchers.  
Besides a gene vector, two other key components are necessary to implement magnetofection namely, 
a suitable magnetic field applicator and properly formulated MNPs.     
 
PHYSICAL PROPERTIES OF MAGNETS AND MNP 
For any biomedical application using MNP-based vectors, the magnetic component of these 
complexes (i.e., the magnetic core) needs to be specifically designed and engineered regarding its 
chemical and magnetic properties, so that the magnetic interaction can be maximized. The underlying 
physical interaction is related to the force generated on the magnetic core of any MNP-based complex, 
when a magnetic particle with magnetic (dipole) moment µ is placed in a non-uniform magnetic field 
B. In such a non-uniform magnetic field the force F exerted on a magnetic dipole with value (µ is 
related to the spatial variation, assumed in the x-direction) of B through its spatial derivatives  
𝑭 = (𝝁 ∙ 𝛁)B (equation 1) 
Figure 3 shows the magnetic field B numerically simulated for a disk-shaped permanent magnet 
(NdFeSm) having 2 cm in diameter and 1 cm in height . The B profile was obtained applying a finite 
element method (FEM) on the corresponding Maxwell equations and boundary conditions. It can be 
seen that the field B decreases from a maximum value at the surface to a 25% of this value just 1 cm 
away from the magnet surface. Moreover the magnetic force, proportional to the derivative dB/dx, 
drops similarly within the same 1 cm distance, making it difficult to apply this simple method for 
obtaining constant forces within any practical working volume.  
From equation (1) it is clear that, from a physical point of view, the MNPs must display the highest 
possible magnetic moment, which is related to the saturation magnetization MS (at room temperature) 
of the core materials. Compounds having large MS include pure 3d transition metals, which are 
extremely difficult to stabilize against oxidation in biological media (Table 1). Among those oxides 
having large MS, rare earths (Nd or Sm) or Ba are unsafe materials regarding toxicity levels. The iron 
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oxides Fe3O4 (magnetite) and α-Fe2O3 (hematite) are the only materials already approved for human 
applications in a variety of clinical protocols. Magnetite has been shown to fulfill the requirements of 
high Curie temperature (TC), high saturation magnetic moment (MS ~ 90-98 emu/g, or ~450-500 
emu/cm3) and low toxicity. Although from the production point of view magnetite is cheap and 
relatively easy to obtain in highly purified form, the manufacture of MNPs featuring magnetically 
ordered cores of few nm in diameter is a major challenge because the high surface/volume ratio causes 
superficial disorder effects to become dominant.  
In magnetofection, the magnetic field is applied to move the MNP-gene vector complexes towards the 
target site. In practice, this means that the target site ought to be subject to a magnetic flux density 
which is sufficient to cause saturation magnetization of the magnetic complex and ought to be subject 
to the highest possible field gradient. For magnetofection in cell cultures this requirement is not 
difficult to fulfil but for in vivo applications, magnets need to be tailor-made according to the anatomy 
of the target region in order to optimize magnetic trapping of complex particles. Magnets in the 96-
well microtiter plate format are commercially available. In these plates Nd-Fe-B cylindrical magnets 
are assembled in antiparallel arrays. They produce a magnetic flux density ranging from 0.13 to 0.24 
T. In contrast, most of the magnets used for in vivo studies have not been optimized in design and 
shape (9).       
 
CHEMICAL AND BIOLOGICAL PROPERTIES OF MNP 
Applications of MNPs in biomedical areas require the use of a colloidal ferrofluid, or magnetic 
colloids, which consist of a suspension of magnetic particles of nanometric sizes in aqueous biological 
fluids (e.g., serum or cerebrospinal fluid (CSF)). These colloids usually have particle concentrations in 
the range of 1015-1017 particles/ml. The stability of any magnetic colloid depends on the balance 
between attractive (van der Waals and dipole-dipole) and repulsive (steric and electrostatic) forces 
between the particles and the surrounding solvent molecules. Temperature is also a relevant parameter 
for stability due to energy transfer from the solvent molecules (Brownian motion) to the nanometric 
particles. Therefore, to stabilize the suspended MNPs against these forces they are often coated with a 
biocompatible polymeric layer. Nanoparticles stabilized by electrically neutral molecules (amphiphilic 
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molecules, as oleic acid or alkylsilanes) constitute a surfacted colloid. Steric repulsion between 
particles acts as a physical barrier that keeps grains in suspension and stabilizes the colloid in nonpolar 
solvents. The polar heads of surfactant molecules can be cationic, anionic, zwitterionic or nonionic. A 
number of biocompatible surfactants/stabilizers have been used to generate MNPs. They include 
derivatized dextrans, starch or polycations such as polyethylenimine (PEI), polylysine (PL), protamine 
sulfate (PS), polycarylic acid and polybrene (PB, hexadimethrine bromide), among others [10]. In 
summary, the requirements that MNPs need to meet in order to be suitable for magnetofection are: 
Surface functionality. The surface of the coating layer of MNPs serves different purposes: (a) it 
stabilizes the MNPs in suspension and  determines their shape during the growth process when they 
are produced; (b) it provides functional groups at the surface for further derivatization with organic 
groups or active biomolecules.  
Functional compatibility with the vector. The association of MNPs with gene vectors or third 
components must not impair the functionality of the vectors concerning DNA delivery and expression. 
Biocompatibility. MNPs have to show low or negligible toxic effects on both cell cultures and in vivo. 
Different kinds of viability assays are to be performed before a given MNP is considered as non-toxic. 
Dispersion stability. MNPs should be available as monodisperse (i.e., nonaggregated) particles 
suspended in suitable physiological fluids. Sample preparation should ensure stability against particle 
precipitation, aggregation and/or self assembly phenomena. 
High magnetic response, in order to induce magnetic complex migration towards and concentration in 
the target area under the effect of an external magnetic field. Proper magnetic field profiles are also 
needed; they are usually designed by numerical simulation of magnet configurations. These 
calculations are in principle capable of engineering efficient magnetic field applicators particularly for 
in vivo use. 
SYNTHESIS OF MNPs 
Magnetic nanoparticles can be produced by a number of physical and chemical routes that differ in the 
final properties of the products.  For an overview on synthesis procedures and characteristics of 
nanoparticles suitable for gene delivery see (11). A broad classification scheme can be made based on 
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the physical state of the starting materials. In the top-down strategy, the starting bulk material is 
reduced to nanometric scale in one (thin films), two (nanowires) or three (nanoparticles, or quantum 
dots) dimensions. This route is often based in physical processes like mechanical alloying, laser 
machining, laser chemical etching, reactive ion etching, among others. On the contrary, the bottom-up 
approach uses atomic or molecular units as starting materials to grow larger, nanometric structures. 
Bottom up techniques include chemical vapor deposition (CVD), reactive sputtering, plasma enhanced 
CVD, pulsed laser deposition (PLD), molecular beam epitaxy (MBE), and also wet routes like sol-gel 
and microemulsion thechniques. Most of the above techniques have attained good control of physical 
parameters of the products such as phase purity, particle shape, crystalline order and the attainable 
range of particle sizes, although tailoring all of these parameters in a single product remains a 
challenging task. Two main approaches for MNP synthesis can be considered.  
 
Thermal decomposition from organic precursors 
Monodisperse iron-oxide nanoparticles of different sizes ranging from 2 to 20 nm can be obtained by 
high temperature (250-350 ºC) decomposition of iron organic precursors (Figure 4) [12]. These MNPs 
can be further functionalized with relevant biological molecules attached to the surface [13]. The 
synthesis method is based on the use of iron (or any transition metal) acetylacetonate (acac) and 
different solvents (e.g., phenyl ether or 1-Octadecene) which lead to different synthesis temperatures. 
To control the final particle size, different precursor/surfactant molar ratios can be used [14].  
This single-step, high-temperature synthesis for Fe3O4 MNPs is governed by the thermal 
decomposition of the precursor Fe(acac)3 in the presence of a long-chain alcohol (e.g., 1,2 octanediol) 
and surfactants (oleic acid and oleilamine) using phenyl ether (boiling point ~533 K) as organic 
medium. For MNPs with <d> < 10 nm, this process can be further modified to tailor the final particle 
sizes through the molar ratio [Fe(acac)3]/[surfactants] as reported by Vargas et al. [15]. The 
nanoparticles obtained usually range from 3 to 12 nm, and are very stable against aggregation because 
of the surfactant molecules attached to the surface. The method has been improved to obtain MNPs 
with <d> > 12 nm by growing previously synthesized MNPs as seeds (~ 10 nm) and repeating the 
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synthesis protocol to further increase the final particle size. In this way, the synthesis of particles up to 
<d> = 25 nm has been reported. 
Oxidative hydrolysis method 
This method, first reported by Matijevic et al. [16], is based on the precipitation of an iron salt (FeSO4) 
in basic media (NaOH) in the presence of a mild oxidant. It was later improved for specific 
applications [17, 18]. Two different approaches have been reported to coat MNPs, including in-situ 
and after–synthesis with organic polymers such as poly L-lysine (PLL), polyethylene glycol (PEG) and 
PEI. In the first approach, the MNPs are coated during the synthesis, while the post-synthesis coating 
method consists on grafting the polymer or surfactant onto the magnetic particles once synthesized.  
 
MAGNETOFECTION IN CELLS  
As already stated, magnetofection was initially developed mainly to enhance gene transfer in cell 
culture, a simpler and more easily controllable scenario than in vivo models. Magnetofection in cell 
lines not only facilitated the optimization of protocols and MNP formulations but it also provided 
evidence for some unique capabilities of this approach. Progressively, an increasing number of 
publications combining magnetofection in cell culture and in experimental animals are beginning to 
emerge. This section will review studies exclusively dealing with magnetofection in cells, leaving for 
the next section the consideration of reports documenting in vivo studies.  
 
Neuronal and glial cells 
Since neurons are sensitive to cytotoxicity and generally difficult to transfect by conventional 
methods, there is a growing interest in developing MNP formulations and magnetofection protocols 
suitable for neuronal cell cultures. One such protocol was optimized for transfection of cDNA and 
RNA interference (short hairpin RNA (shRNA)) into rat hippocampal neurons (embryonic day 18/19) 
cultured for several hours to 21 days. The protocol allowed double-transfection of DNA into a small 
subpopulation of hippocampal neurons (GABAergic interneurons), and achieved long-lasting 
expression of DNA and shRNA constructs without interfering with neuronal differentiation [19]. A 
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specific MNP formulation called NeuroMag, which uses particles ranging in size from 140 to 200 nm 
and possessing a positive zeta potential, has recently been reported to significantly enhance reporter 
gene transfer in mouse neural stem cell (NSC) cultures without showing significant levels of toxicity 
[20]. Magnetofection has been also used for effective gene transfer in cultures of multipotent rat neural 
precursor cells and rat oligodendrocyte precursors [21, 22].  In primary cultures of rat hypothalamic 
neurons, magnetofection was used to transfect the CG and CA alleles of an enhancer sequence related 
to galanin expression [23]. Magnetofection in mouse embryonic motor neurons was used to transfect a 
plasmid encoding the gene for a fluorescent protein fused to the spinal muscular atrophy-disease 
protein Smn. With this approach it was demonstrated that Smn is actively transported along axons of 
live primary motor neurons. Furthermore, magnetofection was also implemented for gene knockdown 
using shRNA-bound constructs [24].  
 
Endothelial and epithelial cells  
Magnetofection has been reported to potentiate gene delivery to cultured primary endothelal cells and 
to human umbilical vein endothelial cells (HUVEC). Thus, up to a 360-fold increase in luciferase gene 
transfer was achieved by magnetofection as compared to various conventional transfection methods 
[25]. Biodegradable polylactide-based MNPs, surface-modified with the D1 domain of CAR as an 
affinity linker, have been affinity bound to a RAd expressing GFP and used to implement 
magnetofection in cultured endothelial and smooth muscle cells. This strategy yielded a stable MNP-
RAd association that displayed efficient gene delivery and rapid cell binding kinetics in the presence 
of a magnetic field. Multiple regression analysis suggested that the mechanism by which the complex 
transduces the cells is different from that of naked adenoviruses [26]. More recently, the development 
of MNPs coated with PEG and with covalently linked branched PEI (bPEI), has been reported. In 
HUVEC cultures, nonviral vector-hybrid MNP complexes exhibited highly efficient magnetofection, 
even in serum conditioned media [27].  
In tissue engineering a major challenge comes from insufficient formation of blood vessels in 
implanted tissues. One approach to overcome this problem has been the production of angiogenic cell 
sheets using a combination of two techniques namely, magnetic cell accumulation and magnetofection 
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with magnetite cationic liposomes (MCLs) coupled to a retroviral vector expressing vascular 
endothelial growth factor (VEGF). VEGF magnetofection in a monolayer of mouse myoblast C2C12 
cells increased transduction efficiency by 6.7-fold compared with a conventional method. Then, MCL-
labeled cells were accumulated in the presence of a magnetic field to promote the spontaneous 
formation of multilayered cell sheets. When these sheets were subcutaneoulsy grafted in nude mice 
they produced thick tissues displaying a high-cell density [28].  Magnetic field- and ultrasound-aided 
delivery of the gene for VEGF(165) to oversized ischemic rat skin flaps was implemented using 
magnetic lipospheres (magnetobubbles) loaded with the corresponding  cDNA. This approach 
increased the survival and perfusion of flaps grafted in rats [29].  
Topical application of DNA vector complexes to the airways faces specific extracellular barriers. In 
particular, short contact time of complexes with the cell surface caused by mucociliary clearance 
hinders cellular uptake of complexes. In order to overcome this limitation magnetofection of the 
luciferase gene was assessed in permanent (16HBE14o-) and primary airway epithelial cells (porcine 
and human) as well as in native porcine airway epithelium ex vivo. Transfection efficiency and dose-
response relationship of the luciferase gene revealed that magnetofection enhanced transfection 
efficiency in both, permanent and primary airway epithelial cells. Magnetofection also induced 
significant transgene expression at very short incubation times in the ex vivo airway epithelium organ 
model [30]. Magnetically guided lentiviral-mediated transduction of bronchial epithelial cells was also 
reported to induce efficient reporter (GFP) gene delivery [31]. In another study, MNPs complexed to 
Lipofectamine 2000 or cationic lipid 67/plasmid DNA (pDNA) liposome complexes were reported to 
be highly effective for gene delivery in airway epithelial cell cultures but less effective than pDNA 
alone when applied in the murine nasal epithelium in vivo. The latter result is likely to be a 
consequence of the significant precipitation of the complexes observed in vivo [32]. 
 
Tumor and embryonic cells 
Hexanoyl chloride-modified chitosan (Nac-6) stabilized iron oxide nanoparticles (Nac-6-IOPs) were 
used in the CAR(!) human leukemia K562 cell line for viral gene (RAd-LacZ) delivery via 
magnetofection. For this complex the authors reported effective magnetofection results in vitro and in 
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vivo [33]. In a recent study, the transfection efficiency (percentage of transfected cells) and therapeutic 
potential (potency of insulin-like growth factor–1 receptor (IGF-1R) knockdown) of liposomal 
magnetofection of plasmids expressing GFP and shRNAs targeting IGF-1R (pGFPshIGF-1Rs) was 
assessed in A549 lung adenocarcinoma cells and in tumor-bearing mice. This method was reported to 
achieve a 3-fold improvement in GFP expression as compared to lipofection using Lipofectamine 
2000. In vitro, IGF-1R specific-shRNA transfected by lipofection and by magnetofection inhibited 
IGF-1R protein by 56.1±6% and 85.1±3%, respectively. In vivo delivery efficiency of the 
pGFPshIGF-1R plasmid into the tumor was significantly higher in the liposomal magnetofection 
group than in the lipofection group [34].  
Magnetofection of cDNA constructs and shRNA into mouse genital ridge tissue was implemented as a 
means of gain-of-function and loss-of-function analysis, respectively. Ectopic expression of Sry 
induced female-to-male sex-reversal, whereas knockdown of Sox9 expression caused male-to-female 
sex-reversal, consistent with the known functions of these genes. Also, ectopic expression of 
Tmem184a, a gene of unknown function, in female genital ridges, resulted in failure of gonocytes to 
enter meiosis. These results suggest that magnetofection may constitute a suitable tool for the study of 
gene function in a broad range of developing organs and tissues [35]. 
 
THERAPEUTIC POTENTIAL OF MAGNETIC GENE TARGETING IN VIVO 
Cancer 
Cancer has been a major target disease for gene therapy since the early days of this technology. 
Currently, a high number of experimental and clinical studies are under way using a wide variety of 
approaches to deliver the cDNA of choice to the tumor cells. The nature of these approaches depends 
on the biological characteristics of the tumor to be treated and include the delivery of genes for 
immunomodulatory molecules, suicide genes, tumor suppressor genes, oncolytic genes and 
antiangiogenic genes, among others [for a review see 36; also see 37, 38]. In many instances the 
above approaches involve invasive procedures when local administration of the vector is required. If 
the therapeutic gene vector is administered intravenously (IV), high doses need to be injected to 
compensate for dilution of the vector in the circulation. This also leads to spreading of the vector 
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throughout the body, with lungs, liver and kidneys accumulating substantial levels of the vector. These 
limitations are also faced by pharmacological approaches using anticancer drugs, which usually are 
significantly toxic for healthy organs. This prompted the development of magnetic carriers and MDT 
whose two main goals are, a) to reduce the invasiveness of drug administration and b) to generate a 
“magnetic cage” in the target area so that the magnetic carriers are trapped and concentrated there. In 
this way lower doses of the antitumor drug would be necessary for achieving therapeutically effective 
intratumor levels. Magnetic trapping would also minimize drug dissemination to the rest of the 
organism.  
Magnetic carriers were first used to target cytotoxic drugs (doxorubicin) to sarcoma tumors implanted 
in rat tails [39]. The initial results were encouraging, showing a total remission of the sarcomas 
compared to no remission in another group of rats which were administered with ten times the dose 
but without magnetic targeting. Since that study, success in cytotoxic drug delivery and tumor 
remission has been reported by several groups using animal models including swine [40, 41], rabbits 
[42] and rats [43, 44, 45]. This technique has also been employed to target cytotoxic drugs to brain 
tumors which are particularly difficult targets due to the fact that the drug must cross the blood brain 
barrier (BBB). It was reported that microparticles 1–2 μm in diameter could be concentrated in an 
intracerebral rat glioma [44]. Although the concentration of the particles in the tumor was low it was 
significantly higher than in controls injected with nonmagnetic particles. Better results were achieved 
in these tumors employing 10–20 nm MNP particles [45]. Electron microscopic analysis revealed the 
presence of MNPs in the interstitial space of the tumors but not in normal brain tissue where MNPs 
were only found in the vasculature. In another study, MDT in rat brain tumors achieved some degree 
of success only when the BBB was disrupted immediately prior to particle injection [46].   
There have been a few trials of MDT in humans although none of them has been followed up and 
currently no major pharmaceutical company has undertaken the development of magnetic drug 
formulations. A Phase I clinical trial demonstrated that the infusion of ferrofluids was well tolerated in 
most of the 14 patients studied [2]. In addition, the authors reported that the magnetic particles were 
successfully directed in advanced sarcomas without associated organ toxicity. Multi-center Phase I 
and II, MDT clinical trials for hepatocellular carcinomas, employing magnetic microspheres to which 
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doxorubicin hydrochloride had been adsorbed, revealed promising preliminary results [47]. Although 
clinical application of MDT still faces technical limitations, pre-clinical and experimental results 
indicate that it is possible to overcome some of the reported problems by means of technical 
improvements of the magnetic delivery systems [2, 48]. Clearly, the prospect of using magnetic 
carrier-gene vector complexes emerges as a promising avenue for cancer gene therapy. This approach 
has been used to implement immunostimulating gene therapy in domestic cats with clinical diagnosis 
of fibrosarcoma. Different doses of a plasmid harboring the gene for either feline Interferon-γ, feline 
interleukin-2 or feline granulocyte-macrophage colony stimulating factor (felGM-CSF) were 
complexed with MNPs. The complexes were intratumorally injected and an external magnetic field 
was applied. The treatment was well-tolerated by most of the animals [49]. In a follow up phase I trial, 
preoperative felGM-CSF gene therapy had favorable results as assessed by the rate of recurrence in 
treated versus (surgery-only) control cats [50]. More recently, Tresilwised et al. [7] examined the 
potential of boosting the efficacy of the oncolytic adenovirus dl520 by associating it with MNP and 
performing magnetic field-guided infection in multidrug-resistant cancer cell cultures and  in a murine 
xenograft model. Upon intratumoral injection and application of a gradient magnetic field, magnetic 
virus complexes exhibited a stronger oncolytic effect than adenovirus alone. 
 
Neurological diseases 
Gene transfer to the central nervous system (CNS) poses significant challenges due to both the relative 
inaccessibility of the brain and the extraordinary complexity of CNS structures. On the other hand, this 
approach offers unique advantages for the long-term delivery of neurotrophic factors to specific CNS 
regions affected by neurodegenerative processes and other neurological pathologies. Although the 
documented results for gene therapy in animal models of Parkinson’s Disease [51-54], Alzheimer 
Disease [55, 56] and other neurological pathologies [57, 58] are promising, up to now the only way to 
administer the therapeutic vectors is via stereotaxic injections in the target brain areas. The 
invasiveness of this procedure significantly limits its eventual implementation in human patients.  
The technology for magnetic field-assisted gene delivery has now advanced to a point from where it 
seems feasible to implement minimally invasive gene therapy strategies for the brain. This approach, 
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which combines MDT and magnetofection, appears particularly suitable for pathologies in which the 
affected brain regions can be reached by the therapeutic molecules when they are released into the 
cerebrospinal fluid (CSF).  In rats, it has been shown that adenoviral vectors injected 
intracerebroventricularly (ICV) efficiently transduce the ependymal cell layer and if they harbor the 
gene for a secreted peptide, it is released into the CSF [59]. The ependymal route has been 
successfully used to implement cytokine-gene therapy in the CNS. In this case, ICV injection of a 
RAd vector expressing human interleukin IL-10 ameliorated disease signs in mice with active 
experimental autoimmune encephalomyelitis (EAE) [60]. Furthermore, it is well-established that the 
delivery of genes encoding IL-10, IL-4, TGF-β, IFN-β, p55TNFR-Ig and p75TNFR-Ig into the CNS, 
is superior to IV administration of the same anti-inflammatory cytokines in the treatment of murine 
EAE [61-63].  In aging rats, ICV implementation of  IGF-I gene therapy ameliorated their deficient 
motor performance [64]. Although the specific mechanisms that favor adenoviral transduction of 
ependymal cells are unknown, this route of gene delivery has numerous advantages including the 
ability to increase the levels of a transgenic therapeutic protein throughout many regions of the CNS. 
It also avoids possible side effects of pharmacologically high circulating levels of therapeutic 
molecules after peripheral administration.  
The ependymal route has been recently used to implement MGT in rodent embryos. Thus, a RAd 
vector tagged with MNPs was ICV injected in mouse embryos in vitro and in vivo. By applying an 
external magnetic field to a limited area of the head of the embryos, transgene delivery was restricted 
to that region [65]. The same route could be exploited to implement minimally invasive therapeutic 
gene delivery in the adult rodent brain by ICV administration of MNP-viral vector complexes at distal 
sites and subsequent magnetic trapping of the complexes at the target brain region by means of a 
properly focused external magnetic field. There are a number of suitable adult animal models available 
for trial [66], one of them being the aging female rat. In effect, it is well-established that in the female 
rat, the hypothalamic dopaminergic (DA) neurons which exert a tonic inhibitory control on prolactin 
secretion, become dysfunctional with age [67]. A significant reversal of chronic hyperprolactinemia 
and  hypothalamic DA neuron dysfunction was achieved by neurotrophic factor gene therapy in the 
hypothalamus of aged female rats [68, 69]. In these studies the therapeutic viral vectors were injected 
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into the hypothalamic parenchyma. It is proposed that similar results could be achieved by a less 
invasive approach involving the injection of MNP-therapeutic viral vector complexes in the cisterna 
magna and subsequently concentrating them by magnetic trapping in the third ventricle (Fig. 5). To 
reach the third ventricle from the cisterna magna the magnetic complexes need to travel counterflow. 
Since CSF flow velocities are over ten times lower than arterial blood flow velocities (0.4 cm/s [70] 
versus 5 cm/s [71], respectively), the strength of the magnetic field to be applied in order to ovecome 
CSF counterflow force remains within the capacity of cylindrically or conically shaped Nd-Fe-B 
permanent magnets. If successful, this proof-of-concept approach could be extended to other regions 
of the brain. 
 
Myocardial Infarction 
Heart failure remains as one of the major causes of morbidity and mortality throughout the world, 
worsening as the population ages. The development of the coronary bypass implant technique and its 
implementation in human patients [72] represented a major achievement for the surgical treatment of 
myocardial ischemia. The search for less invasive approaches led to the development of the 
nonsurgical technique known as percutaneous transluminal coronary angioplasty (PTCA) [73] which 
has revolutionized the treatment of acute coronary failure, preventing or significantly reducing the 
consequences of myocardial infarction (MI). The subsequent development of drug-eluting stents has 
contributed to reduce the incidence of post-angioplasty restenosis due to proliferation and migration of 
medial and intimal smooth muscle cells (SMC) in the treated artery, a significant problem with early 
bare metal stents. Coronary stenting technology has made it conceivable the clinical implementation of 
cardiovascular gene therapy (for a general review on cardiovascular gene and cell therapy see [74]). 
Viral vectors harboring genes for angiogenic, myotrophic or anti-proliferative factors can now be 
delivered in animal models by the use of viral vector-eluting stents. Such strategies have been reported 
in rabbit vascular injury models [75, 76]. One of the current targets of experimental gene therapy 
approaches is to prevent restenosis by local delivery of genes encoding SMC antiproliferative factors. 
For instance, RAd-mediated overexpression of the cyclin/cyclin dependent kinase (CDK) inhibitor 
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p21, was used to inhibit neointima formation in a rat model of balloon angioplasty [77]. In another 
gene therapy approach, transcription decoys using a consensus-binding sequence for transcription 
factor E2F inhibited smooth muscle proliferation in a model of rat carotid injury [78].  
Another aim of cardiovascular gene therapy is to stimulate myocardial angiogenesis in the post-MI 
heart. In a swine model of pacing-induced congestive heart failure, intramyocardial injection of RAd-
VEGF121 increased myocardial perfusion and enhanced its function [79]. At clinical level, in a phase II 
randomized controlled trial using RAd-VEGF121, there was improvement in exercise-induced ischemia 
in patients that received intramyocardial delivery of the therapeutic vector [80]. In patients with 
previous MI or angina, RAd-mediated delivery of VEGF165 or fibroblast growth factor (FGF)-4 was 
reported to be effective in increasing myocardial perfusion [81, 82]. Another important angiogenic 
candidate factor for myocardial gene therapy is IGF-I. Thus, in a rat model of MI, local IGF-I gene 
delivery by an adeno-associated viral vector (AAV) rendered sustained transduction and improved 
cardiac function post-MI [83].  
The combination of intra-arterial gene vector delivery by coronary catheterization with MGT could 
further improve the effectiveness of post-MI gene therapy. MDT studies in mice demonstrated that an 
external stationary magnetic field (ΛB= 200mT/cm) focused on the lung could achieve a significant 
magnetic field and field gradient in the heart (112 mT and 90 mT/cm, respectively) increasing the 
bioavailability of doxorubicin-magnetite nanoparticle conjugates in the mouse lung [84]. This suggests 
that in rodents, IV injection of MNP-gene vector complexes in the presence of a strong external 
magnetic field focused on the heart could achieve a significant concentration of the vector in the 
myocardium. In the first study to demonstrate in vitro and in vivo magnetically targeted gene delivery, 
magnetic microspheres were coated with an AAV2 encoding GFP or human α-1 anti-tripsin (AAT), 
using a cleavable heparin sulphate linker. The complexes induced increased gene delivery in C2 
muscle cells and could be targeted by an external magnetic field. Increased gene delivery was 
achieved in vivo following intramuscular or IV injection of the complexes in mice [85, 86]. In these 
studies, IV injection of the complexes induced higher gene delivery to the heart (and other organs) 
than injection of the vector alone.  
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In spite of the promise these experimental studies offer, it is important to mention that in human 
patients, an external magnet placed over the chest would need to generate a very strong magnetic field 
in order to achieve in the heart, field gradients high enough as to prevent the arterial blood flow from 
washing away the MNP-vector complexes.  
An alternative strategy to improve magnetic force is to insert a magnetizable coronary stent at the 
target site. Under the influence of an external magnetic field, the stent will create locally a high-
gradient magnetic field. This procedure is termed implant-assisted magnetic drug targeting [87-89]. 
The feasibility of this approach was suggested by a study in an isolated swine heart ventricle perfusion 
model carrying an intra-arterial stent coil fabricated from ferromagnetic stainless steel 430 wire and 
used to capture 100-nm diameter magnetite particles that mimicked magnetic drug carrier particles 
[90]. Implant-assisted targeting of magnetic particles under the influence of an external magnetic field 
has previously been verified through mathematical modeling [91, 92], in vitro studies [93], and in vivo 
studies in rat carotid arteries [94, 95] as a feasible method for localized drug delivery. An initial in 
vivo biocompatibility test in pigs, carried out by intravascular injection of the nanoparticles in a 
stented brachial artery, showed no short-term adverse effects. In vitro evaluation in a flow-through 
model proved that the magnetic nanoparticles were captured efficiently to the surface of a 
ferromagnetic coiled wire at the fluid velocities typical for human arteries. A preliminary test of tissue 
plasminogen activator (t-PA)-nanoparticle conjugates in a pig model suggested that the conjugates 
may be used for treatment of in-stent thrombosis in coronary arteries [96].  
The above studies are encouraging and suggest that MGT to the cardiovascular system could be a 
rewarding research avenue and that it merits to be explored further. 
 
CONCLUDING REMARKS 
During the past two decades the biomedical applications of magnetic fields and MNPs have expanded 
remarkably due to the possibilities they open for noninvasive diagnostic and therapeutic approaches.  
In this context, the discovery that MNP-gene vector complexes can, in the presence of a magnetic 
field, greatly enhance gene transfer into cells and eventually allow the development of minimally 
invasive gene delivery approaches in vivo, is raising much interest in this emerging technology. Many 
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of the studies reviewed here constitute important landmarks in the path towards a mature MGT 
technology.  
In his seminal book, Engines of Creation [97], KE Drexler defined nanotechnology as a manufacturing 
methodology based on the manipulation of individual atoms and molecules in order to construct 
complex structures, specified at the atomic level. In practice, Drexlerian nanotechnology remains as an 
embryonic discipline, with its practical implementation lying in the future. What is generally known as 
nanotechnology should be called applied nanoscience which is a discipline in active development. 
Drexlerian theorists imagine a medical branch of nanotechnology called nanomedicine [98]. This 
medical specialty will be based on the use of intelligent nanoinstruments or nanobots which after 
being injected into the bloodstream will survey the body searching for faulty cells, repairing them or 
destroying those beyond repair (Fig. 6, left). These nanobots will be wirelessly controlled by external 
computers. Figure 6 right, diagrammatically represents a current MNP-adenovector complex. It could 
be considered as a gene delivery nanoinstrument. Its central component, the viral vector, has the 
capability to recognize and enter its target cells and deliver to them its therapeutic gene(s). To a certain 
extent it can also be wirelessly controlled, not by a computer, but by a magnetic field. Therefore, if 
Drexlerian nanomedicine becomes a reality in the future, perhaps these magnetic complexes will be 
considered as predecessors of therapeutic nanobots.      
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Table 1. Values of saturation magnetization MS for different magnetic materials used as carriers in 
MDT and magnetofection.  
 
 
Material MS (emu/g) † 
Magnetite Fe3O4 90-92 
Maghemite γ-Fe2O3 84-88 
CoFe2O4 ~75 
Iron (α-Fe) 217.9 
Cobalt 162.7 
Nickel 57.5 
(† values at room temperature.) 
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FIGURE LEGENDS 
 
Figure 1.- Diagrammatic representation of the magnetofection principle in cells. MNPs are 
complexed to RAds and the complex is attracted to cells by a magnetic field.  (Kindly provided by OZ 
Biosciences, Marseille, France, www.ozbiosciences.com). 
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Figure 2.- Magnetofection in 293 cells.- Cell cultures were incubated with either 105 pfu/well RAd-
GFP alone (left image) or with 1 or 4 µl AdenoMag™ MNPs complexed to 105 pfu/well RAd-GFP 
(center and right images, respectively). All cultures were exposed for 25 min to a magnetic field and 
images were taken 4 days afterwards. A higher number of transduced cells is evident in the cells 
incubated with the vector complexed to MNPs. The diagrams below are only intended to qualitatively 
illustrate the reader on the nature of the RAd-MNP complexes. They do not represent actual 
MNP/RAd-GFP ratios or complex structure. RAd-GFP, an adenoviral vector expressing the gene for 
green fluorescent protein. Obj. 20X (Goya, RG, et al., unpublished data).  
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Figure 3.- Numerical simulation of magnetic field amplitude and field gradient for a typical 
cylindrical permanent NdFeSm magnet of 2 cm diameter and 1 cm in height. Left panel: induction 
field B mapping. The polarization is chosen along x axis. B color values are shown on the inset scale. 
Right panel: Induction field profile as a function of distance to the surface, along x- and y-directions. 
Inset: values of the spatial derivative dB/dx (proportional to the magnetic force) along x- and y-
directions taken from the same simulations. 
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Figure 4.- Magnetite (Fe3O4) MNPs prepared by: (a) decomposition of Fe(acac)3 in 1-octadecene, (b) 
precipitation-oxidation of FeSO4 in aqueous media. [Goya, GF et al., unpublished data] 
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Figure 5.- Proposed design for minimizing the invasiveness of gene therapy in the rat 
hypothalamus.  A MNP-RAd complex suspension is injected in the cisterna magna (5 µl) in the 
presence of a conical (or cylindrical) Nd-Fe-B permanent magnet placed in a proper orientation at the 
base of the rat head. The magnetic field drags the ferrofluid upstream the CSF flow towards the 3V 
(the target area) where the magnetic vector particles are concentrated so that the therapeutic transgene 
is delivered to the ependymal cell layer. After injection, the rat and the magnet are left in the same 
position for 30 min with the animal still under anesthesia. The magnetic field lines, magnet orientation 
and other details are intended for illustration only. They represent neither the precise configuration of 
the magnet nor the actual position for injection of head relative to the horizontal plane. The RAd 
virion is represented as a red icosahedron to which MNP (light blue spheres) are bound.  
CM, cisterna magna; SA, Sylvian aqueduct; 3V, 3rd ventricle; LV, lateral ventricle [Goya RG, et al., 
unpublished].     
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Figure 6.- Advanced medical nanobots and current gene delivery nanoinstruments.- Left panel: 
Artist´s view of future therapeutic nanobots injected into the blood stream [Front cover from ref. 98, 
with permission] Right panel: Simplified diagram of a typical  MNP-adenovector complex currently 
used for magnetofection.       
 
 
 
